1:41 PM
 | 
Jun 27, 2017
 |  BC Extra  |  Financial News

Provention raises $28.4M in series A

Autoimmune and inflammatory disease prevention and interception play Provention Bio Inc. (Lebanon, N.J.) said it raised $28.4 million in a series A round from the Johnson & Johnson Innovation-JJDC Inc. arm of Johnson & Johnson (NYSE:JNJ), the JDRF T1D fund and undisclosed private investors. The newco is aiming to conduct an IPO in 2018.

Francisco Leon, former VP and head of translational medicine at J&J's Janssen Biotech Inc. unit, co-founded Provention with CEO Ashleigh Palmer in...

Read the full 372 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >